US FDA Approves Lilly’s Breast Cancer Drug Combo

Inluriyo Plus Verzenio Wins Full FDA Approval for ESR1 Mutated Advanced Breast Cancer After Progression on Endocrine Therapy

The FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer. Median progression-free survival doubled in an ESR1-mutated subgroup.

Lilly wins full FDA nod for Inluriyo combo in breast cancer

Eli Lilly (LLY) wins full FDA approval for its oral SERD Inluriyo in combination with Verzenio for ESR1-mutated ER+/HER2- metastatic breast cancer. Read more here.

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Jonah.Comstock Fri, 18/09/2026

US FDA approves Lilly's breast cancer drug combo

Eli Lilly Stock Ends Flat After FDA Expands Inluriyo–Verzenio Use

Eli Lilly won full U.S. Food and Drug Administration approval on Friday for Inluriyo used with Verzenio in a defined group of patients with advanced breast cancer. The stock barely moved: Lilly shares closed at $1,152.93 on Sept. 18, up 49 cents, or 0.04%, from Thursday. That subdued finish is a useful measure of the…

FDA approves Lilly's oral SERD combo for second-line breast cancer therapy

The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, a regimen that includes Lilly’s oral selective estrogen receptor degrader (SERD) drug Inluriyo. Patients with metastatic ...